Medicare spending on each dose of Sanofi Genzyme’s Renvela has been ratcheting up by an annual growth rate of 21.6 percent for roughly the last five years. Nearly the same is true for Sanofi’s Lantus, Merck’s Zetia, and Amgen’s Enbrel — Medicare spending on all of them climbed by an annual rate of more than 18 percent between 2012 and 2016.
Now the Trump administration is calling out the companies behind those increases as part of an effort to tout its updates to the Centers for Medicare and Medicaid Services “drug pricing dashboard” and the data available there. It updated the dashboard Tuesday as part of its broader effort to put forth policies and changes that will help lower drug prices.
Other drug makers on the administration’s naughty list: Bristol-Myers Squibb for its Orencia and Eliquis products. Pfizer made the list, for Lyrica; Genentech, for Xolair and Rituxan; Abbvie, for its Humira Pen; Novartis, for Sandostatin Lar; Janssen, for Remicade and Xarelto; AstraZeneca, for Crestor; Sunovion for Latuda; Otsuka America, for Abilify; Shire, for Vyvanse. Both Amgen’s Neulasta and Merck’s Januvia were also highlighted.
About the Author Reprints
